(3 years, 1 month ago)
Commons ChamberRead Hansard Text Watch Debate Read Debate Ministerial Extracts
Jon Cruddas (Dagenham and Rainham) (Lab)
I rise to make a series of points about improving allergy services in the UK and to speak in support of numerous recommendations made this week by the all-party parliamentary group on allergy and the National Allergy Strategy Group in their report, “Meeting the challenges of the National Allergy Crisis”. I will begin on a positive note and say how much the allergy community appreciated the fact that the Minister made time in her busy diary to receive the document at her Department on Wednesday morning. She spent time talking to children living with multiple allergies, as well as health professionals and charities. We hope that that will be the beginning of an ongoing dialogue.
Allergy is a hypersensitivity reaction or an exaggerated sensitivity to substances—allergens—that are normally tolerated. Examples include peanuts, milk, shellfish, cats, medicines and grass pollens. They can trigger harmful antibodies and the release of inflammatory chemicals, causing symptoms such as sneezing, itches, rashes and falls in blood pressure, yet they may also cause airway narrowing, shortness of breath and wheezing, and swelling which, if in the mouth, throat or airway, causes severe difficulty in breathing and can be life-threatening.
The simple truth is that there is a modern-day epidemic in allergy—one neglected by the NHS. Recent high-profile tragic cases of fatal anaphylaxis have brought shortcomings in NHS service provision, and a lack of wider public understanding of allergy, into sharp focus. This week’s report therefore calls for a new national strategy to help the millions of people across the UK affected by allergic disease. It also calls for an influential lead for allergy—some have labelled it an allergy tsar—to be appointed who can implement such a strategy.
By way of background, we have been here before, and quite regularly. Over the past two decades, a series of reports have reviewed the prevalence of allergic diseases, consequent patient need and UK service provision. The list includes earlier reports from the all-party parliamentary group that I am fortunate to chair, plus two Royal College of Physicians reports in 2003 and 2010, the first titled, “Allergy: the unmet need”. The 2003 report was so scathing that in 2006, the Department of Health conducted “A review of services for allergy”. We have also had a 2004 Commons Health Committee report on “The Provision of Allergy Services”, as well as the 2007 House of Lords Science and Technology Committee report, “Allergy”. All have consistently highlighted how allergy remains poorly managed across the NHS due to a lack of training and expertise. All recommended significant improvements in specialist services, as well as improved knowledge and awareness in primary care.
That is not to say nothing has changed. We have seen National Institute for Health and Care Excellence guidelines on allergy and care pathways for children with allergic disease, but very little has changed. Allergy remains under-resourced across the national health service, so once again this week’s document makes similar arguments and recommendations to earlier reports. We do not apologise for that, because so little has changed over the past 20 years. Actually that is not entirely the case. Something significant has changed over the past two decades: there has been a dramatic upsurge in the numbers of those affected by various allergic conditions across the country.
The figures speak for themselves. Around one in three people, which is 20 million of our fellow citizens in the UK, have an allergy-related disorder. A significant amount of that is severe or complex, whereby one patient can suffer several disorders, each triggered by different allergens. Five million have conditions severe enough to require specialist care. Fatal and near-fatal reactions occur regularly due to foods, drugs and insect stings and have been increasing over recent years. Hospital admissions due to allergy rose by 52.5% in the six years to 2017-18. Admissions with anaphylaxis—rapid onset and often life-threatening reactions—rose by 29%. It is estimated that one in 1,333 of the population in England has experienced anaphylaxis at some point in their lives.
Prevalence rates for allergy in the UK are among the highest in the world, especially among the young. Some 40% of children in the UK have been diagnosed with some form of allergy. Each year, new births add 43,000 cases of child allergy to the population in need, yet specialist services delivered by trained paediatric allergists are available to only a minority of those with serious disease. One in four adults and about one in eight children in the UK has allergic rhinitis, which includes hay fever and animal and house dust mite allergy. That is roughly 16 million people. They are four times more likely to suffer from asthma, eczema and food allergy. The percentage of people diagnosed with allergic rhinitis, asthma and eczema has trebled over the past four decades.
The overall economic case for prevention-oriented allergy services is very strong. The estimated cost of allergy-related illness in 2004 was £1 billion. Since then, there has been a 200% to 300% increase in anaphylaxis-related admissions. The starkest figure is that primary care visits for allergy have increased to account for 8% of total GP consultations. Put simply, the complexity and severity of allergies have increased, as well as the number of patients affected, placing huge strains on the system. Those are the basic facts. Change is long overdue.
Beyond the statistics, for the growing number of people in the UK living with allergic disease, their condition can have a significant negative impact on their lives and their families’ lives. It is frightening and restrictive to live with a condition that could cause a severe or life-threatening reaction at any time. Despite the shocking statistics, each of the reports that I have mentioned concludes that allergy has largely been ignored and is poorly managed across the NHS owing to a lack of training and a lack of expertise.
The core problem is that there are a very small number of consultants in adult and paediatric allergy, while most GPs receive no training in allergy at all. The basic mismatch between rising demand and poor service supply needs correction. There are only 11 specialist allergy trainee posts for doctors in England, despite the 2004 report’s recommendation of a minimum of 40. Only two qualify each year—fewer than in Lithuania, which has a population of 3 million.
The tiny number of allergy trainees is a bottleneck, stifling growth of the specialty. Shockingly, despite repeat submissions over 20 years to the workforce bodies responsible for trainee numbers, there has been very little increase. There are also too few consultants, only 40 adult allergists and a similar number of paediatric allergists working in a small number of allergy centres across the country.
Most general practitioners receive no training in clinical allergy, either as medical students or in their specialist GP training. The consequences for NHS patients are that they face an extraordinary postcode lottery across the country; that they are hampered by wrong referrals and re-referrals, or get no referral; that they are denied choice and the benefits of improvements in allergy care; and that there is significant and enduring unmet need.
The new training programme in allergy from August 2021 combines allergy with a different specialism in clinical immunology, but the danger is that that will further dilute and downgrade the quality of allergy specialist training. Meanwhile, on the ground, there is growing evidence of a reduction in some allergy services, with closures or restrictions, mainly among secondary care providers, because they are so overburdened.
Paradoxically, the UK is world-leading in allergy research and UK allergy guidelines are highly regarded internationally, yet failure to invest in clinical services nationally means that NHS provision is inconsistent, is often poor and in many areas falls far below that in other developed countries. More generally, the covid-19 pandemic has highlighted a new need for allergists to support the vaccine roll-out. The major new workload that arose—investigating anaphylaxis and suspected allergic reactions to the covid-19 vaccines and providing advice on safe vaccinations—has been delivered by a small cadre of allergists, building on their drug allergy expertise.
All these issues, and the resulting lack of effective allergy care, need to be recognised and corrected by NHS England and Health Education England. Basically, the report makes four recommendations for action. The first is a national plan for allergy, making allergy a priority, investing in a national plan led by a designated Department of Health and Social Care civil servant or NHS lead with sufficient authority to implement change—a national clinical director of allergy—and bringing together medical professionals and patient support organisations to develop the strategy and improve allergy services. The report details a list of organisations that might be involved in the delivery of training programmes to meet allergy need and provide the education across primary care that is needed for health visitors, dieticians and other healthcare professionals.
The second recommendation is on specialist care: to expand the specialist workforce as a priority, and to ensure that training programmes prioritise allergy, so that specialists of the future are appropriately trained and can safely deliver care. It proposes a minimum of 40 additional training posts for allergy, and a minimum of four consultant allergists for adults and two paediatric allergists in every major teaching hospital and large conurbation.
The third recommendation is on primary care: to ensure that all GPs and healthcare professionals in primary care have knowledge of allergic disease; to ensure allergy is included in the GP curriculum and exit examination; to improve allergy education for already qualified GPs in ongoing professional appraisal; and to appoint a health visitor and/or a practice nurse in each practice with sufficient training to be responsible for allergy. Again on a positive note, some of this is beginning to happen. The Royal College of General Practitioners has recently added allergy to new GP exams.
The fourth recommendation is on commissioning: to ensure that local commissioners understand the allergy needs of their population. It says that it is not adequate to assume that other specialties can deliver specialist allergy care; that commissioners should ensure access to adult and paediatric allergy consultants, and allergy pathways; and that national commissioners should ensure national agreements on commissioning, including for immunotherapy, drug allergy investigation and so on.
In conclusion, I hope that the Department will seriously consider the report and its recommendations. Supporting the growth of the allergy speciality would give more patients access to accurate diagnosis, which should surely be expected in a modern national health service. We can all agree that patient safety, the prevention of severe life-threatening reactions and the control of chronic disease are paramount. More specialist allergists are essential to support primary and secondary care, and to improve integrated care, keeping more patients out of hospitals. This would in turn tackle the geographical inequalities and lack of access to specialist allergy services. A relatively small investment would be an effective multiplier and deliver wider dividends.
Such a model would result in better care for patients in line with the NHS long-term plan. The Government and the NHS should give allergy the priority it deserves and recognise the true burden that it can place on those affected, their families and wider communities. They should not have to wait any longer. This report offers the solutions to the problems and makes sensible, achievable recommendations for change. We look forward to them being implemented.
The Minister for Care and Mental Health (Gillian Keegan)
I thank the hon. Member for Dagenham and Rainham (Jon Cruddas) not only for securing this debate on this important issue but for arranging for me to meet, on Wednesday, the wonderful APPG to receive a copy of its report in person.
The Government recognise the challenges faced by people with allergies and are taking a number of actions to further support them. Allergies affect around 20 million people in the UK. For most, they are mild, but for some they are severe and can be fatal. That was the case for 15-year-old Natasha Ednan-Laperouse, who sadly passed away in 2016. Thanks to the tireless work by Natasha’s parents, Tanya and Nadim, and their charity, the Natasha Allergy Research Foundation, Natasha’s law came into force in October this year. That milestone legislation sets out the legal requirement for all food retailers and operators to display full ingredient and allergen labelling information on every food item they sell pre-packed for direct sale. This will give the millions throughout the UK who are living with food allergies and intolerances better protection and more confidence in the food they buy.
We know how important it is that healthcare professionals, people with allergies and those close to them have the information that they need about the safe and effective use of adrenaline auto-injectors—AAIs—when they are administered in an emergency situation. That is why the Medicines and Healthcare Products Regulatory Agency is developing a communications campaign to convey key messages to improve the safe and effective use of AAIs, including the need to carry two AAIs at all times.
People with allergies continue to be supported through locally commissioned services but, to support patients with more complex conditions, NHS England and NHS Improvement also directly commission some specialised services such as specialist allergy clinics.
As with all conditions, we acknowledge that we need to have the right professional support in place for people living with allergies, including national clinical leadership. We have already established a clinical reference group for specialised allergy and immunology services, chaired by Dr Tomaz Garcez, a consultant immunologist. Membership includes clinicians, commissioners, public health experts, patients and carers. They use their combined knowledge and expertise to advise NHS England on the best ways to provide those specialist services. To support clinicians in the implementation of clear care pathways, the NICE website has guidance to support diagnosis and treatment of a range of allergy conditions, including how to identify allergies, when to refer to specialist care, and how to ensure allergies are recorded in people’s medical records.
The importance of getting that right was emphasised to me when I had the privilege of meeting people on Wednesday, when the all-party group shared its report. In particular, I was personally touched by the story of the two young boys I met, Arlo and Monty, who suffer from serious allergies. The report rightly emphasises the need and the importance of having a highly skilled workforce educated in allergy diagnosis and treatment to ensure that they can appropriately support people in managing their conditions. I have agreed to meet the hon. Gentleman and other representatives from the group to discuss that important issue further. I also plan to arrange a roundtable meeting in due course, so we can understand what additional help is required.
On ensuring we have the right workforce in place, there has been some encouraging progress. However, we know that more can be done. We are working with HEE to increase the uptake in available training places. The latest figures to June 2021 show that the number of doctors, and doctors in training, in specialist allergy and immunology has increased. I know there are already many dedicated medical professionals working in allergy and immunology specialisms.
Relevant training is the responsibility of the Royal College of Physicians, with a certificate of completion of training in allergy and immunology available to support specialist allergy care. The RCP also runs an accreditation scheme, improving quality in allergy services. Currently, there are seven accredited NHS trusts in England: North Bristol NHS Trust; Nottingham University Hospitals NHS Trust; Royal Brompton and Harefield Hospital NHS Foundation Trust; University Hospitals of North Midlands NHS Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals of Leicester NHS Trust; and University Hospitals Plymouth NHS Trust. A further 22 trusts across the UK are working towards accreditation. In addition, the British Society for Allergy and Clinical Immunology provides training for primary care staff across the country through workshops and education. The Royal College of General Practitioners has developed an allergy e-learning online resource to support CPD and revalidation, which aims to educate GPs about the various presentations of allergic disease, how to access an atopic patient, and when to investigate in primary care or refer to secondary care.
Looking to the future, we continue to invest in research to improve the health outcomes of those living with allergies. Over the past five years, the Department of Health and Social Care has awarded the National Institute for Health Research over £2 million for research into food allergies. It is currently funding two trials investigating food allergy using oral immunotherapy, including one that compares two treatments for an allergy to cows’ milk in babies and another which seeks to overcome severe allergic reactions to peanuts in adults.
This is a very important debate, and I genuinely thank the hon. Gentleman for bringing it forward. I look forward to working with him to improve services. The NHS works really hard to care for all its patients, including those suffering from allergies, mild or severe. I want to ensure that all adults and children, like Monty and Arlo, living with allergies continue to receive the best care possible and feel safe and confident in the care that they receive. We will continue to work with our delivery partners and stakeholders to ensure that we have the workforce, clinical leadership and expert guidance in place to best support those living with allergies.
Finally, I want to say a special thank you to Arlo and Monty. On Wednesday, during half-term, they gave up their time and, when most other children were out and about enjoying activities, they got here early with their parents to present the report to me. They looked fantastic and spoke very wisely. That really brought home to me the maturity of young children who have to live with allergies, with all the things they need to know and all the personal responsibility they need to take. I will do all that I can to make life better for them and others like them.
Question put and agreed to.